AstraZeneca and Daiichi Sankyo’s Enhertu Shows Strong Phase III Results in HER2-Positive Early Breast Cancer Read more
Dyne Therapeutics’ DYNE-251 Gains Orphan Drug Status in Japan for Duchenne Muscular Dystrophy Read more